Primary Job Title Managing Director Primary Organization Clarus Ventures
Location Needham, Massachusetts, United States Regions Greater Boston Area, East Coast, New England Gender Male
Investor Type
LinkedIn View on LinkedIn
Michael Steinmetz, PhD, has been Managing Director of Clarus Ventures since the firm’s inception in 2005.
Prior to Clarus, Dr. Steinmetz was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 25 years of direct industry and investment experience within the healthcare sector.
From 1986 to 1997, Dr. Steinmetz
was an executive at Hoffmann-LaRoche where he held various positions including Vice President of Preclinical Research and Development, and Global Head of Biotechnology.
Dr. Steinmetz obtained his PhD summa cum laude from the University of Munich and held positions at the California Institute of Technology and the Basel Institute for Immunology.
Dr. Steinmetz represents Clarus Ventures on the Board of Directors of Heptares, Lycera, Oxford, TetraLogic, Variation, and Virdante. In addition, he is a member of the Board of Directors of Allozyne, Macrogenics, and TaiGen.
Previous directorships include Acorda (NASDAQ:ACOR), Amphora, Arena (NASDAQ:ARNA), Atugen/SR Pharma (AIM:SPA), Biovitrum (merged into Swedish Orphan Biovitrum STO:SOBI), BioXell (SWX: BXLN), Caliper (NASDAQ:CALP), CGI Pharmaceuticals (acquired by Gilead), Coelecanth (acquired by Lexicon), ESBATech (acquired by Alcon), Epigenomics (FRK: ECX), GPC Biotech (merged into Agennix FRA:AGX), IDEA AG, Intracel Corp, ISB Accelerator, and VLST Corp.
